Healthcare Global Enterprises Limited

CARE Ratings Ltd. has reported that a company has largely deployed proceeds from a public offering, with funds used for debt prepayment, acquisition of a 34% stake in Vizag Hospital, and general corporate purposes. Approximately Rs. 95.83 crore was allocated to general corporate purposes, covering expenses such as salaries, consultancy, and vendor payments, as outlined in the offer document. The report notes that issue-related expenses were lower than initially projected, allowing for a reallocation of Rs. 0.26 crore to general corporate purposes. All commitments were completed within the timeframe specified in the offer document by Fiscal Year 2027, and the monitoring agency relied on information provided by the company and third-party sources, disclaiming any independent audit or legal liability.

Healthcare Global Enterprises Ltd share price ticked higher by 0.17% to Rs 670.5 after the company's net profit surged by 307.43% to Rs 16.46 crore, while revenue from operations improved marginally 6.63% to Rs 693.39 crore in Q2FY26 over Q1FY26. The market capitalization of Hospital industry group stocks on BSE stood at Rs 5.11 lakh crore, easing 5.20%. It has increased 13.41% over last one week and soared by 31.33% in last one month while the market capitalization of Healthcare Global Enterprises Ltd has marginally improved by 0.28% and 10.80% in the same period respectively. Profit before tax (PBT) of Healthcare Global Enterprises Ltd stood at Rs 25.03 crore in Q2 FY26, surging by 109.98% year-on-year, and jumping 1902.40% quarter-on-quarter. EBITDA came in at Rs 110 crore, gaining 9.08% YoY and slipping 1.68% sequentially. Total expenses grew marginally by 9.02% to Rs 643.26 crore in Q2FY26 over Q2FY25. During the quarter, employee benefits expense was at Rs 104.52 crore, surging 13.03% YoY. For the TTM ended FY26, revenue from operations improved 16.26% to Rs 2218.14 crore, while net profit rose by 18.18% to Rs 48.83 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 34863% to Rs 352.47 crore, and PBT fell 15.89% to Rs 56.96 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 317.11 crore in FY26, as against Rs 284.58 crore in FY25. Healthcare Global Enterprises Ltd rallied 9.55% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.64% during the same period.

HealthCare Global Enterprises Limited announced that its board of directors approved the re-appointment of M/s. Rao Murthy & Associates, Cost Accountants, Bengaluru, as the company’s Cost Auditor for the financial year 2026-27, with Firm Registration No. 000065.

HealthCare Global Enterprises Limited announced that there was no deviation or variation in the utilization of funds raised through its Rights Issue of Rs 424.68 crore during the quarter ended June 30, 2026, from the objects stated in the Letter of Offer dated February 24, 2026, according to a filing with the National Stock Exchange of India Limited and BSE Limited. The company noted a minor difference in issue-related expenses, with Rs 4.81 crore utilized against an estimated allocation of Rs 5.07 crore, resulting in an additional Rs 0.26 crore being used for general corporate purposes.

HealthCare Global Enterprises Limited announced that its board approved a further investment of up to Rs 16 crore in its wholly owned subsidiary, HCG Rajkot Hospitals LLP, for repayment of dues, working capital, and general corporate purposes. HCG Rajkot, incorporated on September 22, 2017, operates a 147-bed cancer specialty hospital in Rajkot, Gujarat, with a turnover of approximately Rs 60.67 crore for the financial year ended March 31, 2026, and the investment is expected to be completed on or before September 30, 2026.

HealthCare Global Enterprises Limited said a subsidiary, HCG Manavata Oncology LLP, has agreed to acquire a 26% equity stake in Epic Vighnaharta Renewable Energy Private Limited (EVRE) for an aggregate consideration of Rs 38 lakh. The acquisition will allow the subsidiary to qualify as a captive user of a solar power plant being set up by EVRE in Maharashtra, enabling EVRE to supply electricity to the LLP for its own use.

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 6 August 2026.

Total operating expenditure for the period under review was Rs 559.16 crore, up 16.6% YoY. The company recorded an exceptional charge of Rs 31.91 crore in the March 2026 quarter. HealthCare Global stated that during the quarter and year ended 31 March 2026, the management committed to a plan to divest the company's entire equity interest in BACC Healthcare (BACC), a wholly owned subsidiary engaged in the management of infertility treatment hospitals. Pursuant to the investor outreach process, non-binding offers were received from potential investors. Accordingly, the assets and liabilities of BACC have been classified as a disposal group held for sale as at 31 March 2026. Along with the classification as held for sale, the carrying amount of goodwill allocated to the cash-generating unjt (i.e., BACC) was assessed for impainnent and an impairment loss of Rs 31.91 crore has been recognised as an exceptional item for the quarter and year ended 31 March 2026 based on the net fair value of the consideration receivable. Accordingly, profit before tax in Q4 FY26 stood at Rs 1.25 crore in Q4 FY26, down by 90.8% from Rs 13.62 crore in Q4 FY25. For FY26, the company has recorded consolidated net profit and revenue from operations of Rs 13.76 crore (down 69% YoY) and Rs 2,538.43 crore (up 14.4% YoY), respectively. HealthCare Global Enterprises (HCG) is India's largest dedicated cancer hospital network, operating 25 hospitals across India and Africa. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. Under 'Milann', HCG operates fertility centers as well. The scrip rose 1.58% to currently trade at Rs 656.90 on the BSE. Powered by Capital Market - Live

Net profit of Healthcare Global Enterprises declined 70.52% to Rs 2.17 crore in the quarter ended March 2026 as against Rs 7.36 crore during the previous quarter ended March 2025. Sales rose 11.46% to Rs 650.29 crore in the quarter ended March 2026 as against Rs 583.43 crore during the previous quarter ended March 2025. For the full year,net profit declined 69.02% to Rs 13.76 crore in the year ended March 2026 as against Rs 44.41 crore during the previous year ended March 2025. Sales rose 14.44% to Rs 2538.43 crore in the year ended March 2026 as against Rs 2218.14 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales650.29583.43 11 2538.432218.14 14 OPM %19.2318.11 -18.3517.46 - PBDT95.9771.69 34 315.67268.30 18 PBT33.1613.62 143 71.5056.96 26 NP2.177.36 -71 13.7644.41 -69 Powered by Capital Market - Live

Healthcare Global Enterprises has today launched its new comprehensive cancer hospital in Hebbal with up to 132 beds, strengthening access to advanced oncology care in North Bengaluru (HCG Cancer Hospital, Hebbal). The new facility marks a major advancement in the region's oncology landscape, bringing together clinical excellence, compassionate care and advanced technology to make world-class cancer treatment more accessible to people across Karnataka. Marking a significant milestone in precision oncology, the new facility introduces Karnataka's first Elekta Unity MR-Linac, one of the world's most advanced precision radiation therapy platforms. The technology combines high-quality MRI imaging with a linear accelerator to enable highly precise, adaptive cancer treatment. Designed as a full-spectrum oncology centre, the hospital brings together diagnosis, treatment, recovery support, and patient-centric care under one roof, making world-class cancer care more accessible to patients across North Bengaluru.